This activity is expired and is no longer available for CME credit.


Updates in Immunotherapy – Philadelphia 2015

Author(s)/Faculty: Sanjiv S. Agarwala, MD; Roy S. Herbst, MD, PhD; Eric J. Sherman, MD
Release Date: 8/18/2015Expiration Date: 8/17/2016
Credit Type: CMENumber of Credits: 0
Content Type: VideoProvider:
The promise of immunotherapy in oncology has become a reality with the US Food and Drug Administration (FDA) approval of the programmed death-1 (PD-1) inhibitor pembrolizumab and the cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) inhibitor ipilimumab for treatment of advanced melanoma, the approval of the PD-1 inhibitor nivolumab for treatment of advanced squamous non-small cell lung cancer (NSCLC), and the FDA Breakthrough Therapy Designation to pembrolizumab for the treatment of patients with EGFR mutation-negative and ALK rearrangement-negative NSCLC whose disease has progressed on or following platinum-based chemotherapy. In addition, nivolumab, pembrolizumab, and other checkpoint inhibitors are showing promise in clinical trials for the treatment of other cancers, for which the currently available therapies show very limited benefit. Combination regimens of checkpoint inhibitors, as well as checkpoint inhibitors and targeted therapies/radiation therapy, also are being evaluated. Equally important, significant advances have been made in the use of biomarkers to help identify patients who are the best candidates for these therapies. Within this rapidly evolving scenario, it is critical for oncologists to remain up-to-date with advances in immunotherapy, utilize approved agents in patients who are appropriate candidates, and be better prepared to utilize agents as they are approved. In this CME activity, leading experts discuss the most recent advances in immunotherapy, focusing on melanoma, NSCLC, as well as head, neck, and other cancers.